Skip to main content

Truseltiq Side Effects

Generic name: infigratinib

Medically reviewed by Drugs.com. Last updated on Nov 3, 2023.

Note: This document contains side effect information about infigratinib. Some dosage forms listed on this page may not apply to the brand name Truseltiq.

Applies to infigratinib: oral capsules.

Side effects include:

Most common (≥20%) adverse reactions include nail toxicity, stomatitis, dry eye, fatigue, alopecia, palmar-plantar erythrodysesthesia syndrome, arthralgia, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, diarrhea, dry skin, decreased appetite, blurred vision, and vomiting.

Most common laboratory abnormalities (≥20%) include increased creatinine, increased phosphate, decreased phosphate, increased alkaline phosphatase, decreased hemoglobin, increased lipase, increased calcium, decreased lymphocytes, decreased sodium, increased triglycerides, increased ALT/AST, increased urate, decreased platelets, decreased leukocytes, decreased albumin, increased bilirubin, and decreased potassium.

For Healthcare Professionals

Applies to infigratinib: oral capsule.

Hematologic

Very common (10% or more): Decreased hemoglobin (53%), decrease lymphocytes (43%), decreased platelets (37%), decreased leukocytes (26%), decreased neutrophils (14%), decreased albumin (24%), increased urate (37%)[Ref]

Musculoskeletal

Very common (10% or more): Arthralgia (32%), pain in extremity (17%)

Common (1% to 10%): Fractures[Ref]

Ocular

Very common (10% or more): Dry eye (44%), eyelash changes (25%), blurred vision (21%), cataracts (12%)[Ref]

Metabolic

Very common (10% or more): Increased phosphate (90%), decreased phosphate (64%), increased lipase (44%), increased calcium (43%), decreased sodium (41%), decreased calcium (10%), increased potassium (17%), decreased potassium (21%), decrease weight (15%)[Ref]

Hepatic

Very common (10% or more): Increased triglycerides (38%), increased alkaline phosphatase (54%), increased alanine aminotransferase (51%), increased cholesterol (18%), increased bilirubin (24%), increased aspartate aminotransferase (38%), increased lipase (44%)[Ref]

Respiratory

Very common (10% or more): Epistaxis (18%)[Ref]

Nervous system

Very common (10% or more): Fatigue (44%), dysgeusia (32%)[Ref]

Renal

Very common (10% or more): Increased creatinine (93%)[Ref]

Cardiovascular

Very common (10% or more): Edema/peripheral edema (17%)[Ref]

Dermatologic

Very common (10% or more): Nail toxicity (57%), alopecia (38%), dry skin (23%), palmar-plantar erythrodysesthesia syndrome (33%)[Ref]

Gastrointestinal

Very common (10% or more): Stomatitis (56), constipation (30%), abdominal pain (26%), dry mouth (25%), diarrhea (24%), vomiting (21%), nausea (19%), dyspepsia (17%)[Ref]

General

Serious adverse reactions in 2% or more patients included infections, anemia, pyrexia, abdominal pain, hypercalcemia, and sepsis. Fatal adverse reactions occurred in 1 (0.9%) patient. Adverse reactions requiring permanent discontinuation in 1% or more patients were blood creatinine increased, fatigue, subretinal fluid, and calcinosis.[Ref]

References

1. Product Information. Truseltiq (infigratinib). QED Therapeutics Inc. 2021.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.